Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Accelerated and intensified manufacturing of an adenovirus-vectored vaccine to enable rapid outbreak response.
Journal article
Joe CCD. et al, (2023), Biotechnology and bioengineering
Measurement of Adenovirus-Based Vector Heterogeneity.
Journal article
Hickey JM. et al, (2023), Journal of pharmaceutical sciences, 112, 974 - 984
Rapid-response manufacturing of adenovirus-vectored vaccines
Journal article
Joe CCD. et al, (2023), Nature Biotechnology
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Journal article
Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial
Journal article
Jenkin D. et al, (2022), The Lancet Microbe, 3, e663 - e671
Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies.
Journal article
Ng WM. et al, (2022), Cell host & microbe, 30, 1219 - 1230.e7
STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.
Journal article
Padron-Regalado E. et al, (2022), Scientific reports, 12
Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies
Preprint
Ng WM. et al, (2022)
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Journal article
Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific TH1 response with a diverse TCR repertoire
Journal article
Swanson PA. et al, (2021), Science Translational Medicine, 13
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Journal article
Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040
Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Journal article
Dulal P. et al, (2021), Scientific reports, 11
Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.
Journal article
Dulal P. et al, (2021), Scientific reports, 11
Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations.
Journal article
Berg A. et al, (2021), Vaccines, 9
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
Journal article
Frater J. et al, (2021), The Lancet HIV, 8, e474 - e485
T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.
Preprint
Swanson PA. et al, (2021)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trial
Journal article
Clemens SC. et al, (2021)
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116